Related Experiment Videos
Major clinical research advances in gynecologic cancer in 2016: 10-year special edition
Dong Hoon Suh1, Miseon Kim1, Kidong Kim1
1Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea.
Abstract:
In 2016, 13 topics were selected as major research advances in gynecologic oncology. For ovarian cancer, study results supporting previous ones regarding surgical preventive strategies were reported. There were several targeted agents that showed comparable responses in phase III trials, including niraparib, cediranib, and nintedanib. On the contrary to our expectations, dose-dense weekly chemotherapy regimen failed to prove superior survival outcomes compared with conventional triweekly regimen. Single-agent non-platinum treatment to prolong platinum-free-interval in patients with recurrent, partially platinum-sensitive ovarian cancer did not improve and even worsened overall survival (OS). For cervical cancer, we reviewed robust evidences of larger-scaled population-based study and cost-effectiveness of nonavalent vaccine for expanding human papillomavirus (HPV) vaccine coverage. Standard of care treatment of locally advanced cervical cancer (LACC) was briefly reviewed. For uterine corpus cancer, new findings about appropriate surgical wait time from diagnosis to surgery were reported. Advantages of minimally invasive surgery over conventional laparotomy were reconfirmed. There were 5 new gene regions that increase the risk of developing endometrial cancer. Regarding radiation therapy, Post-Operative Radiation Therapy in Endometrial Cancer (PORTEC)-3 quality of life (QOL) data were released and higher local control rate of image-guided adaptive brachytherapy was reported in LACC. In addition, 4 general oncology topics followed: chemotherapy at the end-of-life, immunotherapy with reengineering T-cells, actualization of precision medicine, and artificial intelligence (AI) to make personalized cancer therapy real. For breast cancer, adaptively randomized trials, extending aromatase inhibitor therapy, and ribociclib and palbociclib were introduced.
Insights
Gynecologic oncology research in 2016 highlighted surgical strategies and targeted agents for ovarian cancer, while HPV vaccine cost-effectiveness and advanced cervical cancer treatments were explored. Advances in uterine corpus cancer and general oncology, including AI, were also noted.
Area of Science:
- Gynecologic Oncology
- Cancer Research
- Clinical Trials
Background:
- 2016 saw significant research advances across gynecologic oncology.
- Key areas included ovarian, cervical, and uterine corpus cancers, alongside general oncology topics.
Purpose of the Study:
- To summarize major research findings and clinical trial outcomes in gynecologic oncology from 2016.
- To highlight advancements in surgical strategies, targeted therapies, and treatment modalities.
Main Methods:
- Review of published studies and clinical trial results from 2016.
- Analysis of data concerning surgical interventions, chemotherapy regimens, targeted agents, and radiation therapy.
Main Results:
- Ovarian cancer research supported surgical prevention and evaluated targeted agents (niraparib, cediranib, nintedanib), but dose-dense chemotherapy and single-agent non-platinum treatments showed limited survival benefits.
- Cervical cancer research emphasized HPV vaccine cost-effectiveness and reviewed standard treatments for locally advanced disease.
- Uterine corpus cancer studies reported on surgical timing, minimally invasive surgery benefits, and identified new genetic risk factors.
- Radiation therapy advancements included quality of life data for endometrial cancer and improved local control with image-guided brachytherapy for cervical cancer.
- General oncology topics covered end-of-life chemotherapy, T-cell immunotherapy, precision medicine, and artificial intelligence in personalized cancer therapy.
- Breast cancer research introduced adaptively randomized trials and new therapeutic strategies involving aromatase inhibitors, ribociclib, and palbociclib.
Conclusions:
- 2016 research provided critical insights into ovarian cancer treatment efficacy, HPV vaccine utility, and uterine corpus cancer management.
- Advancements in radiation therapy, immunotherapy, and the integration of AI are shaping the future of personalized cancer care.